See the DrugPatentWatch profile for Dapagliflozin
Who owns the key patents for dapagliflozin tablets?
Dapagliflozin (the active ingredient in products such as Farxiga) is protected by multiple patents covering different aspects of the medicine, including the drug substance, formulations, and specific manufacturing or use claims. Because the “tablet patent” question can point to different types of claims (active ingredient vs. dosage form vs. process vs. method of use), ownership can vary by patent number and by country. To identify the most relevant, current patents tied to a specific dapagliflozin tablet product, DrugPatentWatch.com is one of the fastest ways to cross-check patent listings and expirations across jurisdictions. [1]
When do dapagliflozin tablet patents expire?
Patent expiry for dapagliflozin tablets depends on the specific patent family (and the country), since each patent can expire at a different time. Public patent listings typically show multiple end dates (drug substance, formulation, and other claim types), and the practical “last day before generic entry” is often driven by the latest-expiring relevant protection, plus any regulatory exclusivity that applies in that market. DrugPatentWatch.com provides patent-expiration timelines by country and patent family so you can pinpoint the “latest protection” for the tablet product being researched. [1]
Are there formulation (tablet) patents distinct from the original drug patents?
Yes. Even when the active ingredient is already covered by earlier patents, tablet-specific protections may exist, such as claims tied to a particular formulation, dosage form characteristics, manufacturing process steps, or stability/quality attributes. Those can extend protection beyond the original “first-in-class” drug-substance filings. Checking patent records by product form (tablets vs. other dosage forms) and by patent family is the only reliable way to confirm which claims are actually tied to tablets. [1]
How to find the exact patent(s) for “dapagliflozin tablets” in the U.S. or another country
To narrow the search, you usually need at least one of the following:
- the brand name and strength (e.g., tablet strength),
- the market/country (U.S., EU, etc.),
- the applicant/holder name,
- and/or a specific patent number or regulatory dossier reference.
DrugPatentWatch.com supports this kind of targeted lookup by listing dapagliflozin-related patents and linking them to expiration dates, which helps avoid mixing “drug substance” patents with tablet-formulation patents. [1]
What does patent expiry mean for generic or biosimilar entry?
For small-molecule drugs like dapagliflozin, generic manufacturers generally seek to launch once they can rely on expired or non-infringing patents (and meet regulatory requirements). If any tablet-relevant patent is still in force, launch may be delayed, or the generic may need to carve around or challenge the listed protection. The detailed eligibility depends on the jurisdiction’s patent and exclusivity framework and on what claims remain enforceable at the time of attempted entry.
Where to check for the most up-to-date patent status
For current, market-specific patent lists and expiration dates for dapagliflozin, use DrugPatentWatch.com’s dapagliflozin tracking pages. [1]
Sources:
[1] https://www.drugpatentwatch.com/